PALVELLA THERAPEUTICS INC (PVLA) Stock Price, Quote, News and Overview
NASDAQ:PVLA - Nasdaq - US6979471090 - Common Stock - Currency: USD
PVLA Quote, Performance and Key Statistics
NASDAQ:PVLA (5/5/2025, 8:00:01 PM)
23.86
-0.6 (-2.45%)
The current stock price of PVLA is 23.86 USD. In the past month the price decreased by -0.5%.
PVLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.09 | 346.84B | ||
| AMGN | AMGEN INC | 13.49 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 128.59B | ||
| GILD | GILEAD SCIENCES INC | 13.28 | 128.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.62 | 65.17B | ||
| ARGX | ARGENX SE - ADR | 345.61 | 40.09B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.58B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.40B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.30B | ||
| NTRA | NATERA INC | N/A | 21.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.81B | ||
| BIIB | BIOGEN INC | 7.7 | 17.85B |
Related stock screener links
About PVLA
Company Profile
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The company is headquartered in Wayne, Pennsylvania and currently employs 14 full-time employees. The company went IPO on 2014-12-18. The firm is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The firm's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Company Info
PALVELLA THERAPEUTICS INC
125 Strafford Ave, Suite 360
Wayne PENNSYLVANIA US
Employees: 14
Phone: 14842531461
PALVELLA THERAPEUTICS INC / PVLA FAQ
What is the stock price of PALVELLA THERAPEUTICS INC today?
The current stock price of PVLA is 23.86 USD. The price decreased by -2.45% in the last trading session.
What is the ticker symbol for PALVELLA THERAPEUTICS INC stock?
The exchange symbol of PALVELLA THERAPEUTICS INC is PVLA and it is listed on the Nasdaq exchange.
On which exchange is PVLA stock listed?
PVLA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PALVELLA THERAPEUTICS INC stock?
15 analysts have analysed PVLA and the average price target is 50.32 USD. This implies a price increase of 110.9% is expected in the next year compared to the current price of 23.86. Check the PALVELLA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PALVELLA THERAPEUTICS INC worth?
PALVELLA THERAPEUTICS INC (PVLA) has a market capitalization of 262.94M USD. This makes PVLA a Micro Cap stock.
How many employees does PALVELLA THERAPEUTICS INC have?
PALVELLA THERAPEUTICS INC (PVLA) currently has 14 employees.
What are the support and resistance levels for PALVELLA THERAPEUTICS INC (PVLA) stock?
PALVELLA THERAPEUTICS INC (PVLA) has a support level at 23.78 and a resistance level at 26.24. Check the full technical report for a detailed analysis of PVLA support and resistance levels.
Is PALVELLA THERAPEUTICS INC (PVLA) expected to grow?
The Revenue of PALVELLA THERAPEUTICS INC (PVLA) is expected to grow by 20.37% in the next year. Check the estimates tab for more information on the PVLA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PALVELLA THERAPEUTICS INC (PVLA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PVLA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PVLA, evaluating the profitability, health, valuation and growth aspects
- PALVELLA THERAPEUTICS INC (PVLA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PALVELLA THERAPEUTICS INC (PVLA) Sales and EPS estimates to see what analysts future expectations are.
- PALVELLA THERAPEUTICS INC (PVLA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PALVELLA THERAPEUTICS INC (PVLA) Insider and Institutional Ownership to learn about the owners and their transactions.
- PALVELLA THERAPEUTICS INC (PVLA) Stock Chart to make your own analysis
- PALVELLA THERAPEUTICS INC (PVLA) Latest news and press-releases to stay up to date.
Does PALVELLA THERAPEUTICS INC (PVLA) stock pay dividends?
PVLA does not pay a dividend.
When does PALVELLA THERAPEUTICS INC (PVLA) report earnings?
PALVELLA THERAPEUTICS INC (PVLA) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of PALVELLA THERAPEUTICS INC (PVLA)?
PALVELLA THERAPEUTICS INC (PVLA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-36).
What is the Short Interest ratio of PALVELLA THERAPEUTICS INC (PVLA) stock?
The outstanding short interest for PALVELLA THERAPEUTICS INC (PVLA) is 2.29% of its float. Check the ownership tab for more information on the PVLA short interest.
PVLA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PVLA.
PVLA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PVLA. PVLA has a great financial health rating, but its profitability evaluates not so good.
PVLA Financial Highlights
Over the last trailing twelve months PVLA reported a non-GAAP Earnings per Share(EPS) of -36. The EPS increased by 34.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.74% | ||
| ROE | -98.06% | ||
| Debt/Equity | 0 |
PVLA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PVLA. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 99.01% and a revenue growth 20.37% for PVLA